drugset / Trial / NCT00978731
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
NaSingle-groupOpen-labelTreatment
Summary
To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 50 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 240 mg | Oral |